Article info
Regular and Young Investigator Award Abstracts
Cell Therapies
239 Engineering of potency-enhanced TCR-edited T cells for shared neoantigen-targeted cancer immunotherapy
Citation
239 Engineering of potency-enhanced TCR-edited T cells for shared neoantigen-targeted cancer immunotherapy
Publication history
- First published November 7, 2022.
Online issue publication
April 26, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.